Show simple item record

dc.contributor.authorDavid, Sabrina
dc.contributor.authorVitale, Alessandra Maria
dc.contributor.authorFucarino, Alberto
dc.contributor.authorScalia, Federica
dc.contributor.authorVergilio, Giuseppe
dc.contributor.authorde Macario, Everly Conway
dc.contributor.authorMacario, Alberto J.L.
dc.contributor.authorBavisotto, Celeste Caruso
dc.contributor.authorPitruzzella, Alessandro
dc.date.accessioned2021-02-08T18:13:40Z
dc.date.available2021-02-08T18:13:40Z
dc.date.issued2021-01-27
dc.identifier.urihttp://hdl.handle.net/10713/14505
dc.description.abstractHsp60 is one of the most ancient and evolutionarily conserved members of the chaperoning system. It typically resides within mitochondria, in which it contributes to maintaining the organelle’s proteome integrity and homeostasis. In the last few years, it has been shown that Hsp60 also occurs in other locations, intracellularly and extracellularly, including cytosol, plasmacell membrane, and extracellular vesicles (EVs). Consequently, non‐canonical functions and interacting partners of Hsp60 have been identified and it has been realized that it is a hub molecule in diverse networks and pathways and that it is implicated, directly or indirectly, in the development of various pathological conditions, the Hsp60 chaperonopathies. In this review, we will focus on the multi‐faceted role of this chaperonin in human cancers, showing the contribution of intra‐ and extracellular Hsp60 in cancer development and progression, as well as the impact of miRNA‐mediated regulation of Hsp60 in carcinogenesis. There are still various aspects of this intricate biological scenario that are poorly understood but ongoing research is steadily providing new insights and we will direct attention to them. For instance, we will highlight the possible applications of the Hsp60 involvement in carcinogenesis not only in diagnosis, but also in the development of specific anti‐cancer therapies centered on the use of the chaperonin as therapeutic target or agent and depending on its role, pro‐ or anti‐tumor. © 2021 by the author.en_US
dc.description.urihttps://doi.org/10.3390/app11031175en_US
dc.publisherMDPI AGen_US
dc.relation.ispartofApplied Sciences (Switzerland)en_US
dc.subjectCarcinogenesisen_US
dc.subjectChaperonopathiesen_US
dc.subjectChaperonotherapyen_US
dc.subjectExtracellular vesicle (EV)en_US
dc.subjectHsp60en_US
dc.subjectMiRNAen_US
dc.titleThe challenging riddle about the janus‐type role of hsp60 and related extracellular vesicles and miRNAs in carcinogenesis and the promises of its solutionen_US
dc.typeArticleen_US
dc.identifier.doi10.3390/app11031175
dc.source.volume11
dc.source.issue3
dc.source.beginpage1
dc.source.endpage18


This item appears in the following Collection(s)

Show simple item record